Completed PHASE1 INTERVENTIONAL 2-arm NCT03446976

CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects

A Phase 1, Randomized, Open-label, Single-dose, Two-arm, Parallel Group Study to Compare the Pharmacokinetics and Safety of the Pre-filled Syringe and Auto-injector of CT-P13 in Healthy Subjects

Sponsor: Celltrion

Conditions Health, Subjective

Interventions CT-P13 SC Auto-injector CT-P13 SC Pre-filled Syringe

Updated 7 times since 2018 Last updated: Jul 25, 2019 Started: Feb 21, 2018 Primary completion: Jul 26, 2018 Completion: Jul 26, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Health, Subjective and is currently completed. Celltrion leads this study, which shows 7 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Aug 2019 — Jan 2021 [monthly]

Completed PHASE1
Nov 2018 — Aug 2019 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed

▶ Show 2 earlier versions

Jun 2018 — Nov 2018 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Mar 2018 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Feb 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celltrion

Data source: Celltrion

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Austin, United States